Opus Genetics to Present Three Studies at ASCRS Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IRD?
Source: Newsfilter
- Research Presentation: Opus Genetics will showcase three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, which evaluates the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting the company's strength in ophthalmology research.
- Clinical Trial Updates: The encore presentation of LYNX-2 will explore the impact of phentolamine ophthalmic solution on visual disturbances in low-light conditions, indicating the product's potential to improve patient visual quality and possibly drive future market applications.
- Educational Symposium Support: Opus's partner Viatris has provided independent funding for an educational symposium titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” aimed at fostering peer exchange and supporting clinicians in managing presbyopia, thereby enhancing the company's influence in the professional community.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating that 2.1 billion people globally will be affected by 2030; Opus's research and product development align perfectly with this vast market demand, presenting significant commercial potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRD
Wall Street analysts forecast IRD stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.500
Low
6.00
Averages
8.00
High
9.00
Current: 5.500
Low
6.00
Averages
8.00
High
9.00
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opus Genetics Presents New Research at ASCRS Meeting
- Research Presentation: Opus Genetics will present three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, evaluating the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting its potential in vision restoration.
- Clinical Trial Updates: Results from the LYNX-2 study will be showcased again, focusing on the improvement of visual disturbances in low-light conditions for post-refractive surgery patients using 0.75% phentolamine, underscoring its clinical relevance.
- Collaboration and Funding: The global licensing agreement with Viatris supports the development of 0.75% phentolamine, with Viatris providing independent funding for an educational symposium aimed at enhancing peer-to-peer exchange among clinicians.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating 2.1 billion globally by 2030, positioning Opus's research to address this growing market need with effective treatment solutions.
See More
Opus Genetics to Present Three Studies at ASCRS Annual Meeting
- Research Presentation: Opus Genetics will showcase three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, which evaluates the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting the company's strength in ophthalmology research.
- Clinical Trial Updates: The encore presentation of LYNX-2 will explore the impact of phentolamine ophthalmic solution on visual disturbances in low-light conditions, indicating the product's potential to improve patient visual quality and possibly drive future market applications.
- Educational Symposium Support: Opus's partner Viatris has provided independent funding for an educational symposium titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” aimed at fostering peer exchange and supporting clinicians in managing presbyopia, thereby enhancing the company's influence in the professional community.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating that 2.1 billion people globally will be affected by 2030; Opus's research and product development align perfectly with this vast market demand, presenting significant commercial potential.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement: Opus Genetics has entered into a financing agreement with Oberland Capital Management, providing up to $155 million in non-dilutive funding, including an initial $35 million tranche and a $5 million equity investment, aimed at supporting the development and commercialization of its inherited retinal disease pipeline.
- Clear Funding Purpose: The funding will be utilized for development, manufacturing, and potential commercialization, particularly for pivotal studies of OPGx-LCA5 and OPGx-BEST1, while also advancing earlier-stage candidates into clinical trials, enhancing the company's competitive edge in gene therapy.
- Cash Flow Extension: With a current cash position of approximately $100 million, the financing is expected to extend Opus's cash runway into 2029, ensuring the company can continue to advance key programs and meet future funding needs.
- Positive Market Reaction: Following the financing announcement, Opus Genetics saw its stock price rise by 1.12% in pre-market trading to $4.60 per share, reflecting market confidence in the company's future growth and positive investor sentiment.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement Details: Opus Genetics has entered into a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding, including an upfront payment of $35 million and a $5 million equity investment, aimed at accelerating the development of early-stage gene therapy programs.
- Cash Flow Extension: With approximately $100 million in current cash, combined with the new financing, the company expects to extend its cash runway into 2029, supporting pivotal studies for OPGx-LCA5 and OPGx-BEST1, thereby enhancing its market competitiveness.
- Clinical Trial Progress: Topline results from the Phase 1 trial of OPGx-BEST1 are expected in mid-2026, and if successful, will propel the company's further development in gene therapy, increasing shareholder value significantly.
- Strategic Investment Significance: This financing not only provides Opus with a flexible capital structure but also supports its global development of innovative therapeutic solutions to meet high unmet medical needs, further solidifying its market position.
See More
Opus Genetics Reports 29.2% Revenue Growth in FY 2025
- Financial Performance: Opus Genetics reported a GAAP EPS of -$0.80 for FY 2025, yet achieved revenue of $14.2 million, reflecting a 29.2% year-over-year growth, indicating strong growth potential in collaborative projects.
- Collaboration Revenue: The company generated $14.2 million in licensing and collaboration revenue from Viatris, Inc. in FY 2025, up from $11.0 million in FY 2024, highlighting sustained demand for its R&D services.
- Cash Position: As of December 31, 2025, Opus Genetics had cash and cash equivalents of $45.1 million and raised approximately $25.0 million through a private placement, enhancing its financial flexibility.
- Operational Funding Outlook: The company believes its total cash resources of $70.1 million will fund operations into the first half of 2028, excluding any potential proceeds from callable warrants or future milestone payments, demonstrating long-term operational sustainability.
See More
Opus Genetics Reports Positive Clinical Data for OPGx-BEST1 Therapy
- Safety and Tolerability: OPGx-BEST1 therapy demonstrated excellent tolerability over a three-month observation period, with no ocular inflammation or treatment-related adverse events, establishing a solid foundation for future clinical applications.
- Functional and Structural Improvement: The treated eye exhibited a 12-letter gain in Best Corrected Visual Acuity (BCVA) and a 23% reduction in Central Subfield Thickness (CST) at three months, indicating the therapy's potential to improve visual function and structure, offering new hope for patients.
- Clinical Trial Progress: Recruitment is ongoing at two clinical sites in the U.S., with full cohort data expected in mid-2026, which will provide critical insights for further clinical development and advance the application of gene therapy.
- Market Demand and Strategic Significance: With no approved treatments for BEST1-related retinal diseases, the positive preliminary results of OPGx-BEST1 not only address this significant unmet medical need but also potentially enhance Opus Genetics' competitive position in the gene therapy market.
See More
Opus Genetics Presents New Research at ASCRS Meeting
- Research Presentation: Opus Genetics will present three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, evaluating the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting its potential in vision restoration.
- Clinical Trial Updates: Results from the LYNX-2 study will be showcased again, focusing on the improvement of visual disturbances in low-light conditions for post-refractive surgery patients using 0.75% phentolamine, underscoring its clinical relevance.
- Collaboration and Funding: The global licensing agreement with Viatris supports the development of 0.75% phentolamine, with Viatris providing independent funding for an educational symposium aimed at enhancing peer-to-peer exchange among clinicians.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating 2.1 billion globally by 2030, positioning Opus's research to address this growing market need with effective treatment solutions.
See More
Opus Genetics to Present Three Studies at ASCRS Annual Meeting
- Research Presentation: Opus Genetics will showcase three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, which evaluates the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting the company's strength in ophthalmology research.
- Clinical Trial Updates: The encore presentation of LYNX-2 will explore the impact of phentolamine ophthalmic solution on visual disturbances in low-light conditions, indicating the product's potential to improve patient visual quality and possibly drive future market applications.
- Educational Symposium Support: Opus's partner Viatris has provided independent funding for an educational symposium titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” aimed at fostering peer exchange and supporting clinicians in managing presbyopia, thereby enhancing the company's influence in the professional community.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating that 2.1 billion people globally will be affected by 2030; Opus's research and product development align perfectly with this vast market demand, presenting significant commercial potential.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement: Opus Genetics has entered into a financing agreement with Oberland Capital Management, providing up to $155 million in non-dilutive funding, including an initial $35 million tranche and a $5 million equity investment, aimed at supporting the development and commercialization of its inherited retinal disease pipeline.
- Clear Funding Purpose: The funding will be utilized for development, manufacturing, and potential commercialization, particularly for pivotal studies of OPGx-LCA5 and OPGx-BEST1, while also advancing earlier-stage candidates into clinical trials, enhancing the company's competitive edge in gene therapy.
- Cash Flow Extension: With a current cash position of approximately $100 million, the financing is expected to extend Opus's cash runway into 2029, ensuring the company can continue to advance key programs and meet future funding needs.
- Positive Market Reaction: Following the financing announcement, Opus Genetics saw its stock price rise by 1.12% in pre-market trading to $4.60 per share, reflecting market confidence in the company's future growth and positive investor sentiment.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement Details: Opus Genetics has entered into a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding, including an upfront payment of $35 million and a $5 million equity investment, aimed at accelerating the development of early-stage gene therapy programs.
- Cash Flow Extension: With approximately $100 million in current cash, combined with the new financing, the company expects to extend its cash runway into 2029, supporting pivotal studies for OPGx-LCA5 and OPGx-BEST1, thereby enhancing its market competitiveness.
- Clinical Trial Progress: Topline results from the Phase 1 trial of OPGx-BEST1 are expected in mid-2026, and if successful, will propel the company's further development in gene therapy, increasing shareholder value significantly.
- Strategic Investment Significance: This financing not only provides Opus with a flexible capital structure but also supports its global development of innovative therapeutic solutions to meet high unmet medical needs, further solidifying its market position.
See More
Opus Genetics Reports 29.2% Revenue Growth in FY 2025
- Financial Performance: Opus Genetics reported a GAAP EPS of -$0.80 for FY 2025, yet achieved revenue of $14.2 million, reflecting a 29.2% year-over-year growth, indicating strong growth potential in collaborative projects.
- Collaboration Revenue: The company generated $14.2 million in licensing and collaboration revenue from Viatris, Inc. in FY 2025, up from $11.0 million in FY 2024, highlighting sustained demand for its R&D services.
- Cash Position: As of December 31, 2025, Opus Genetics had cash and cash equivalents of $45.1 million and raised approximately $25.0 million through a private placement, enhancing its financial flexibility.
- Operational Funding Outlook: The company believes its total cash resources of $70.1 million will fund operations into the first half of 2028, excluding any potential proceeds from callable warrants or future milestone payments, demonstrating long-term operational sustainability.
See More
Opus Genetics Reports Positive Clinical Data for OPGx-BEST1 Therapy
- Safety and Tolerability: OPGx-BEST1 therapy demonstrated excellent tolerability over a three-month observation period, with no ocular inflammation or treatment-related adverse events, establishing a solid foundation for future clinical applications.
- Functional and Structural Improvement: The treated eye exhibited a 12-letter gain in Best Corrected Visual Acuity (BCVA) and a 23% reduction in Central Subfield Thickness (CST) at three months, indicating the therapy's potential to improve visual function and structure, offering new hope for patients.
- Clinical Trial Progress: Recruitment is ongoing at two clinical sites in the U.S., with full cohort data expected in mid-2026, which will provide critical insights for further clinical development and advance the application of gene therapy.
- Market Demand and Strategic Significance: With no approved treatments for BEST1-related retinal diseases, the positive preliminary results of OPGx-BEST1 not only address this significant unmet medical need but also potentially enhance Opus Genetics' competitive position in the gene therapy market.
See More
